← All trials
NCT05812872
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2017
- Primary completion
- Sep 23, 2018
- Completion date
- Jan 20, 2019
- First posted
- Apr 14, 2023
- Last posted
- Apr 19, 2023
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityOverall official - principal investigator
- Ain Shams UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.